Myeloid leukemia
MONDO:0004643A clonal proliferation of myeloid cells and their precursors in the bone marrow, peripheral blood, and spleen. When the proliferating cells are immature myeloid cells and myeloblasts, it is called acute myeloid leukemia. When the proliferating myeloid cells are neutrophils, it is called chronic myelogenous leukemia.
Also known as: leukaemia granulocytic, leukaemia myeloid, leukemia granulocytic, leukemia myelogenous, leukemia myeloid, leukemia, granulocytic, malignant, myelocytic leukaemia, myelocytic leukemia
4342 clinical trials for this condition and its sub-types, 30 tagged with Myeloid leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myeloid leukemia
-
Acute myeloid leukemia 1,097 trials · 1,192 incl. sub-types
78 sub-types
- Acute leukemia of ambiguous lineage 53 trials · 145 incl. sub-types Sub-types →
- Therapy related acute myeloid leukemia and myelodysplastic syndrome 87 trials · 88 incl. sub-types Sub-types →
- Acute myeloid leukemia by FAB classification 0 trials · 59 incl. sub-types Sub-types →
- Acute myeloid leukemia with multilineage dysplasia 34 trials
- Acute myeloid leukemia with mutated NPM1 25 trials
- Inherited acute myeloid leukemia 1 trial · 25 incl. sub-types Sub-types →
- Childhood acute myeloid leukemia 24 trials
- Acute myeloid leukemia, MLL gene rearrangement 23 trials
- Acute monocytic leukemia 20 trials Sub-types →
- Acute myeloid leukemia, FLT3 internal tandem duplication 18 trials
- Acute myeloid leukemia with 11q23 abnormalities 11 trials
- Acute myeloid leukemia, inv(16)(p13.1;q22) 10 trials
- Acute myeloid leukemia, t(16;16)(p13.1;q22) 10 trials
- Acute myeloid leukemia with BCR-ABL1 7 trials
- Acute myeloid leukemia with t(8;21)(q22;q22) translocation 7 trials
- Acute myeloid leukemia, del(5q31-q32) 5 trials
- Acute myeloid leukemia, t(8;21)(q22; q22.1) 5 trials
- Core binding factor acute myeloid leukemia 5 trials
- Acute myeloid leukemia with CEBPA somatic mutations 1 trial
- Acute myeloid leukemia with t(6;9)(p23;q34) 1 trial
- Acute myeloid leukemia, FLT3 tyrosine kinase domain point mutation 1 trial
- Acute myeloid leukemia, biallelic CEBPA gene mutation 1 trial
- Acute myeloid leukemia, t(15;17)(q24;q21) 1 trial
- Acute myeloid leukemia, t(v;11q23.3) 1 trial
- Acute myeloid leukemia with CBFA2T3-GLIS2 fusion 0 trials
- Acute myeloid leukemia with FUS-ERG fusion 0 trials
- Acute myeloid leukemia with MNX1-ETV6 fusion 0 trials
- Acute myeloid leukemia with NPM1 somatic mutations 0 trials
- Acute myeloid leukemia with NPM1-MLF1 fusion 0 trials
- Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 0 trials
- Acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 0 trials
- Acute myeloid leukemia with t(8;16)(p11;p13) translocation 0 trials
- Acute myeloid leukemia with t(9;11)(p22;q23) 0 trials
- Acute myeloid leukemia, CEBPA gene mutation 0 trials
- Acute myeloid leukemia, GATA1 gene mutation 0 trials
- Acute myeloid leukemia, KIT exon 17 mutation 0 trials
- Acute myeloid leukemia, KIT exon 8 mutation 0 trials
- Acute myeloid leukemia, KIT gene mutation 0 trials
- Acute myeloid leukemia, KRAS gene mutation 0 trials
- Acute myeloid leukemia, Monosomy 5 0 trials
- Acute myeloid leukemia, Monosomy 7 0 trials
- Acute myeloid leukemia, NRAS gene mutation 0 trials
- Acute myeloid leukemia, Non-KMT2A MLLT10 rearrangement positive 0 trials
- Acute myeloid leukemia, PTPN11 gene mutation 0 trials
- Acute myeloid leukemia, RUNX1 gene mutation 0 trials
- Acute myeloid leukemia, Trisomy 8 0 trials
- Acute myeloid leukemia, WT1 gene mutation 0 trials
- Acute myeloid leukemia, del(13q14-q21) 0 trials
- Acute myeloid leukemia, der12p 0 trials
- Acute myeloid leukemia, inv(16)(p13.3;q24.3) 0 trials
- Acute myeloid leukemia, inv(3)(q21.3;q26.2) 0 trials
- Acute myeloid leukemia, loss of chromosome 17p 0 trials
- Acute myeloid leukemia, monoallelic CEBPA gene mutation 0 trials
- Acute myeloid leukemia, t(10;11)(p11.2;q23) 0 trials
- Acute myeloid leukemia, t(10;11)(p12;q23) 0 trials
- Acute myeloid leukemia, t(11;15)(p15;q35) 0 trials
- Acute myeloid leukemia, t(11;17) 0 trials
- Acute myeloid leukemia, t(11;19)(q23.3;p13.3) 0 trials
- Acute myeloid leukemia, t(11;19)(q23;p13) 0 trials
- Acute myeloid leukemia, t(11;19)(q23;p13.1) 0 trials
- Acute myeloid leukemia, t(16;21)(p11;q22) 0 trials
- Acute myeloid leukemia, t(16;21)(q24;q22) 0 trials
- Acute myeloid leukemia, t(1;11)(q21;q23) 0 trials
- Acute myeloid leukemia, t(1;22) 0 trials
- Acute myeloid leukemia, t(1;22)(p13;q13) 0 trials
- Acute myeloid leukemia, t(2;12) 0 trials
- Acute myeloid leukemia, t(3;12)(q23;p12.3) 0 trials
- Acute myeloid leukemia, t(3;3)(q21.3;q26.2) 0 trials
- Acute myeloid leukemia, t(3;5)(q25;q34) 0 trials
- Acute myeloid leukemia, t(4;11)(q21;q23) 0 trials
- Acute myeloid leukemia, t(5;11)(q35;p15) 0 trials
- Acute myeloid leukemia, t(6;11)(q27;q23) 0 trials
- Acute myeloid leukemia, t(6;9)(p23;q34.1) 0 trials
- Acute myeloid leukemia, t(7;12)(q36;p13) 0 trials
- Acute myeloid leukemia, t(8;16) 0 trials
- Acute myeloid leukemia, t(9;11)(p21.3;q23.3) 0 trials
- Acute myeloid leukemia, t(9;22)(q34.1;q11.2) 0 trials
- Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) 0 trials
-
Chronic myelogenous leukemia, BCR-ABL1 positive 211 trials · 253 incl. sub-types
3 sub-types
Most studied deeper sub-types
-
New hope for rare blood cancer: experimental drug targets mast cells
Disease control Recruiting nowThis study tests an experimental drug called CGT9486 (bezuclastinib) in people with advanced systemic mastocytosis, a rare and serious blood disorder. The drug aims to control the disease by blocking a key protein that drives abnormal mast cell growth. About 140 adults with aggre…
Phase 2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo targets resistant leukemia
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs, gilteritinib and momelotinib, for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goal is to find a safe dose of momelotinib when given with gilteritini…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New immune cell combo aims to stop leukemia relapse
Disease control Recruiting nowThis early-phase study tests whether giving specially trained immune cells (CIML NK cells) along with a targeted drug (venetoclax) can safely help prevent acute myeloid leukemia (AML) from coming back. Ten adults with AML who have already received standard treatment will receive …
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New Triple-Drug attack on tough leukemia enters human testing
Disease control Recruiting nowThis early-phase study tests whether adding a new drug called eganelisib to two standard AML medications (venetoclax and azacitidine) is safe for people with acute myeloid leukemia that has come back or not responded to treatment. About 48 adults will take part to find the best d…
Phase 1 • Sponsor: Jacqueline Garcia, MD • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug cocktail takes aim at Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage trial is testing a new drug called ziftomenib combined with standard chemotherapy or another targeted drug for people with relapsed or treatment-resistant acute myeloid leukemia (AML) that has specific genetic changes. The main goal is to see if these combination…
Phase 1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New transplant recipe aims to tame Graft-Versus-Host disease
Disease control Recruiting nowThis study tests a stem cell transplant using a reduced-intensity conditioning regimen (lower doses of chemotherapy and radiation) followed by a donor stem cell infusion. The goal is to treat various blood cancers and blood disorders while lowering the risk of graft-versus-host d…
Phase 2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called ICG415 CAR-T cells for adults with acute myeloid leukemia that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack leukemia cel…
Phase 1 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Supercharged immune cells aim to stop leukemia relapse
Disease control Recruiting nowThis early-phase trial tests whether specially trained natural killer (NK) cells, called CIML NK cells, along with interleukin-2 (IL-2), can safely prevent leukemia from coming back after a stem cell transplant. The study enrolls 15 adults with high-risk acute myeloid leukemia, m…
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can pressurized oxygen boost stem cell transplants?
Disease control Recruiting nowThis early-phase study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard stem cell transplant preparation is safe and helps recovery. It involves 24 adults with various blood cancers, such as leukemia and myelofibrosis. Th…
Early phase 1 • Sponsor: Omar Aljitawi • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for hard-to-treat leukemia: old drug shows promise in combo therapy
Disease control Recruiting nowThis early-stage study tests whether adding mitoxantrone to the usual venetoclax+azacitidine regimen can help adults with acute myeloid leukemia (AML) whose cancer did not respond or came back after initial treatment. About 30 participants will receive different doses to find the…
Phase 1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Exercise plus supplement may rebuild muscle in young transplant survivors
Disease control Recruiting nowThis study tests whether a tailored exercise program combined with a dietary supplement called nicotinamide riboside (NR) can improve muscle mass, strength, and fitness in adolescents and young adults who had a bone marrow transplant for leukemia or other blood disorders. About 8…
Phase 2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill shows promise for leukemia patients who've run out of options
Disease control Recruiting nowThis study tests an oral drug called HQP1351 in people with chronic myeloid leukemia (CML) or a type of acute lymphoblastic leukemia (Ph+ ALL) that has not responded to at least two other treatments. The goal is to find the right dose and see how safe and effective the drug is. A…
Phase 1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Could a 'smart' stem cell transplant free patients from a lifetime of anti-rejection drugs?
Disease control Recruiting nowThis early-phase study tests a new stem cell transplant method for people with aggressive or hard-to-treat acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The approach uses specially engineered donor cells to reduce the risk of graft-versus-host disease, potentia…
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New pill takes on tough blood cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests an experimental oral drug called BH-30236 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study first tests BH-30236 alone, then in combination with another drug, venetoclax. About 17…
Phase 1 • Sponsor: BlossomHill Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Exercise may turn back the clock for blood cancer survivors
Knowledge-focused Recruiting nowThis study looks at whether a tailored exercise program can help older blood cancer survivors slow down the aging process. Researchers will enroll 180 people aged 50 and older who have had blood cancer. The goal is to see if participants can stick with the exercise plan and if it…
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC